ArticleMolecular biology reports2025
AdipoRon promotes angiogenesis in B-cell leukemia by modulating pro-angiogenic factors through AdipoR1.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdiponectin, a cytokine predominantly secreted by adipose tissue, is increasingly recognized for its role in cancer, including hematologic malignancies. However, its involvement in leukemia-related angiogenesis remains poorly understood. Here, we investigated the effects of AdipoRon, an adiponectin agonist, on angiogenesis in the JVM-2 lymphoblastic cell line, a model for B-cell leukemia.
methodsThe effects of AdipoRon were assessed on human umbilical vein endothelial cells (HUVECs) and JVM-2 cells using the tube formation assay. The expression of VEGF receptors, VEGF-A, HIF-1α, and CXCL-1 were investigated at both mRNA by quantitative real-time PCR and protein levels by ELISA and Western Blotting. The role of AdipoR1 and AdipoR2 in mediating AdipoRon effects was investigated by siRNA-mediated silencing of each receptor.
resultsAdipoRon significantly promoted angiogenesis in HUVECs, both directly and through the secretion of soluble factors from JVM-2 cells. Treatment with AdipoRon upregulated VEGF-A and its receptors, with VEGF-R2 showing the most prominent increase. Additionally, both HIF-1α and CXCL-1 were up-regulated following AdipoRon administration. Finally, silencing of AdipoR1, but not AdipoR2, diminishes the AdipoRon-induced upregulation of the angiogenesis-related factors, suggesting that AdipoR1 is the primary receptor mediating the effects of adiponectin in leukemia cells.
conclusionOur findings demonstrated that AdipoRon promotes angiogenesis in B-cell leukemia by enhancing pro-angiogenic factors through AdipoR1highlighting adiponectin's significance in angiogenesis. A better understanding of adiponectin's mechanisms could facilitate the development of therapeutic strategies targeting its pathway to inhibit tumor angiogenesis, offering promising approaches for leukemia treatment. Further studies are needed to fully explore adiponectin potential in leukemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.